< Back to previous page
Researcher
Tim Lammens
- Keywords:acute myeloid leukemi, inherited predisposition for cancer, asparaginase, neuroblastoma, juvenile myelomonocytic leukemia, pediatric oncology
- Disciplines:Molecular and cell biology not elsewhere classified, Oncology not elsewhere classified, Genomics, Paediatrics
Affiliations
- Department of Internal Medicine and Pediatrics (Department)
Member
From1 Oct 2018 → Today - Department of Pediatrics and medical genetics (Department)
Member
From1 Jun 2009 → 30 Sep 2018 - Department of Plant Biotechnology and Bioinformatics (Department)
Member
From1 Oct 2004 → 31 Jan 2009
Projects
1 - 10 of 16
- Evaluating the predictive power of a set of adrenergic and mesenchymal coding - and - noncoding RNAs in neuroblastoma.From1 Mar 2024 → TodayFunding: Foreign foundations, funds with scientific view
- Facility : Patiënt-afgeleide xenograft modellen – UGent;From1 Feb 2024 → TodayFunding: BOF - research organisations
- Establishing safety and efficacy of an improved Asparaginase in dog models: final preparation for Phase I clinical trialFrom1 Jan 2024 → TodayFunding: Nonprofit institution or equivalents
- A SIOPEN pragmatic clinical trial to MOnitor NeuroblastomA relapse with LIquid biopsy Sensitive AnalysisFrom1 Jan 2024 → TodayFunding: HORIZON.2.1 - Health
- Towards clinical testing of novel stabilized less toxic asparaginases for the treatment of acute lymphoblastic leukemiaFrom20 Dec 2023 → TodayFunding: IOF - technology validation in lab
- Research assignment of Prof. dr. Tim Lammens, framing the ongoing clinical-translational research at the Department of Pediatric Hematology-Oncology and Stem Cell TransplantationFrom1 Oct 2023 → TodayFunding: Nonprofit institution or equivalents
- Preclinical validation of a less toxic variant for paediatric leukemiaFrom1 Oct 2022 → 30 Sep 2023Funding: Nonprofit institution or equivalents
- A patient derived xenograft (PDX) platform for in vivo evaluation of novel anticancer therapiesFrom1 May 2022 → TodayFunding: FWO Medium Size Research Infrastructure
- The impact of magnetic particulate matter (mPM) pollution as a contributing factor for development of childhood cancer: an in vitro and in vivo molecular and cellular analysis.From1 Nov 2021 → 31 Oct 2022Funding: Nonprofit institution or equivalents
- The use of a less toxic alternative asparaginase variant to treat metastatic breast cancerFrom1 Oct 2021 → TodayFunding: BOF - projects